|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Maryland Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MarylandLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Neuralstem, Inc.
| | | Phone: | (301) 366-4960 | Year Established: | 1996 | Ticker: | CUR | Exchange: | NYSE | Main Contact: | Jim Scully, Interim CEO | | Other Contacts: | Thomas Hazel, Ph.D., Senior VP, Research David Recker, MD, FACR, FACP, CMO Jonathan Lloyd Jones, CFO Karl Johe, Ph.D., Scientific Founder & CSO
| | Company Description | Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. The company is in an FDA-approved Phase I safety clinical trial for ALS, and is also targeting major CNS conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some CNS conditions. The company has completed an FDA-approved Phase Ia safety trial evaluating NSI-189, its first neuroregenerative small molecule compound, for the treatment of major depressive disorder, and expects to receive approval for the Phase Ib trial, in depressed patients, in the fall. Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder. | |
|
|
|
|
|